Cytiva recently entered into a Technology Investment Agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and Joint Program Executive Office (JPEO) at the Department of Defense to increase manufacturing capacity for single-use consumables and hardware at the Massachusetts facilities and Logan, Utah site. As one of the main suppliers to companies developing COVID-19 vaccine candidates, expanding capacity at both sites will enable Cytiva to respond to COVID-19 vaccine demands, while also delivering for customers continuing to work on and develop other therapies. For more information about Cytiva's efforts to address COVID-19 click here.